- Home
- GLSI
as 07-26-2024 4:00pm EST
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | STAFFORD |
| Market Cap: | 197.1M | IPO Year: | 2020 |
| Target Price: | $36.00 | AVG Volume (30 days): | 73.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.58 - $21.44 | Next Earning Date: | 08-19-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Greenwich LifeSciences Inc. (GLSI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Snehal | GLSI | CEO and CFO | Jul 23 '24 | Buy | $15.89 | 1,500 | $23,835.00 | 5,527,102 | SEC Form 4 |
| Thompson Jaye | GLSI | VP Clinical Reg Affairs | Jul 18 '24 | Buy | $16.00 | 1,000 | $16,000.00 | 261,348 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Jun 13 '24 | Buy | $14.30 | 174,825 | $2,499,997.50 | 5,525,602 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Apr 1 '24 | Buy | $19.08 | 3,000 | $57,240.00 | 5,350,777 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Mar 22 '24 | Buy | $19.98 | 2,500 | $49,950.00 | 5,347,777 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Mar 20 '24 | Buy | $17.68 | 1,500 | $26,520.00 | 5,345,277 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Mar 5 '24 | Buy | $12.49 | 3,500 | $43,715.00 | 5,343,777 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Mar 5 '24 | Buy | $12.49 | 30,500 | $380,945.00 | 5,343,777 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Mar 4 '24 | Buy | $13.03 | 4,100 | $53,423.00 | 5,340,277 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Feb 16 '24 | Buy | $11.16 | 10,800 | $120,528.00 | 5,336,177 | SEC Form 4 |
| Patel Snehal | GLSI | CEO and CFO | Feb 15 '24 | Buy | $11.07 | 12,700 | $140,589.00 | 5,325,377 | SEC Form 4 |
Latest Greenwich LifeSciences Inc. News
GLSI Breaking Stock News: Dive into GLSI Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Buyers & Sellers for 07/25/2024
MT Newswires
a month ago
Greenwich LifeSciences to Join Russell 2000 Index; Shares Rise
GlobeNewswire
a month ago
Greenwich LifeSciences Set to Join Russell 2000 Index Again
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/18/2024
GuruFocus.com
a month ago
Insider Buying: CEO and CFO Snehal Patel Acquires Shares of Greenwich LifeSciences Inc (GLSI)
MT Newswires
a month ago
Greenwich Lifesciences Insider Bought Shares Worth $2,499,998, According to a Recent SEC Filing
MT Newswires
a month ago
Greenwich LifeSciences' CEO Acquires $2.5 Million in Shares
GlobeNewswire
a month ago
Greenwich LifeSciences Announces $2.5 Million Private Placement
Compare GLSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLSI Greenwich LifeSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.